{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T04:06:50Z","timestamp":1788926810231,"version":"build-2803163510"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Metab Brain Dis"],"DOI":"10.1007\/s11011-026-01961-2","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T03:38:08Z","timestamp":1788925088000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapeutics candidates and repurposing strategies to target parkinson\u2019s disease pathology: current evidence and future directions"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-4867-2079","authenticated-orcid":false,"given":"Yarava","family":"Dhanush","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6023-7398","authenticated-orcid":false,"given":"N D","family":"Nizamuddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satrasala","family":"Neelima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Kalpana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalyan Kumar","family":"Arla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vakkalagadda Siva","family":"Ganesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P Chandana","family":"Sree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chennuru","family":"Rohitha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"issue":"3","key":"1961_CR1","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1002\/mds.1090","volume":"16","author":"JE Ahlskog","year":"2001","unstructured":"Ahlskog JE, Muenter MD (2001) Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 16(3):448\u2013458","journal-title":"Mov Disord"},{"issue":"2","key":"1961_CR2","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s00429-014-0718-8","volume":"220","author":"V Annese","year":"2015","unstructured":"Annese V, Herrero MT, Di Pentima M, Gomez A, Lombardi L, Ros CM, De Stefano ME (2015) Metalloproteinase-9 contributes to inflammatory glia activation and nigro-striatal pathway degeneration in both mouse and monkey models of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinsonism. Brain Struct Funct 220(2):703\u2013727","journal-title":"Brain Struct Funct"},{"issue":"5","key":"1961_CR3","doi-asserted-by":"publisher","first-page":"e142","DOI":"10.1038\/cddis.2011.17","volume":"2","author":"C Barcia","year":"2011","unstructured":"Barcia C, Ros CM, Annese V et al (2011) IFN-\u03b3 signaling, with the synergistic contribution of TNF-\u03b1, mediates cell specific microglial and astroglial activation in experimental models of Parkinson\u2019s disease. Cell Death Dis 2(5):e142","journal-title":"Cell Death Dis"},{"issue":"4","key":"1961_CR4","doi-asserted-by":"publisher","first-page":"100645","DOI":"10.1016\/j.medj.2025.100645","volume":"6","author":"BR Bloem","year":"2025","unstructured":"Bloem BR, Macklin EA, Schwarzschild MA (2025) GLP-1 agonists to slow down Parkinson\u2019s progression? The quest continues. Med 6(4):100645. https:\/\/doi.org\/10.1016\/j.medj.2025.100645","journal-title":"Med"},{"issue":"47","key":"1961_CR5","doi-asserted-by":"publisher","first-page":"19209","DOI":"10.1074\/jbc.M117.815126","volume":"292","author":"M Boselli","year":"2017","unstructured":"Boselli M, Lee BH, Robert J et al (2017) An inhibitor of the proteasomal deubiquitinating enzyme USP14 induces tau elimination in cultured neurons. J Biol Chem 292(47):19209\u201319225. https:\/\/doi.org\/10.1074\/jbc.M117.815126","journal-title":"J Biol Chem"},{"issue":"2","key":"1961_CR6","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1001\/archneurol.2010.260","volume":"68","author":"JM Bronstein","year":"2011","unstructured":"Bronstein JM, Tagliati M, Alterman RL, Lozano AM, Volkmann J, Stefani A, Horak FB, Okun MS, Foote KD, Krack P, Pahwa R, Henderson JM, Hariz MI, Bakay RA, Rezai A, Marks WJ Jr, Moro E, Vitek JL, Weaver FM, Gross RE, DeLong MR (2011) Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues. Arch Neurol 68(2):165\u2013171. https:\/\/doi.org\/10.1001\/archneurol.2010.260","journal-title":"Arch Neurol"},{"issue":"11","key":"1961_CR7","doi-asserted-by":"publisher","first-page":"e9014","DOI":"10.15252\/emmm.201809014","volume":"10","author":"J Chakraborty","year":"2018","unstructured":"Chakraborty J et al (2018) USP14 inhibition corrects an in vivo model of impaired mitophagy. EMBO Mol Med 10(11):e9014","journal-title":"EMBO Mol Med"},{"issue":"6","key":"1961_CR9","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/ana.21995","volume":"67","author":"HC Cheng","year":"2010","unstructured":"Cheng HC, Ulane CM, Burke RE (2010) Clinical progression in Parkinson disease and the neurobiology of axons. Ann Neurol 67(6):715\u2013725","journal-title":"Ann Neurol"},{"issue":"13","key":"1961_CR8","doi-asserted-by":"publisher","first-page":"3904","DOI":"10.1158\/0008-5472.CAN-15-2534","volume":"76","author":"G Cheng","year":"2016","unstructured":"Cheng G, Zielonka J, Ouari O et al (2016) Mitochondria-targeted analogues of metformin exhibit enhanced antiproliferative and radiosensitizing effects in pancreatic cancer cells. Cancer Res 76(13):3904\u20133915. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-2534","journal-title":"Cancer Res"},{"issue":"5","key":"1961_CR10","doi-asserted-by":"publisher","first-page":"318","DOI":"10.4274\/balkanmedj.galenos.2022.2022-7-100","volume":"39","author":"E \u00c7\u0131nar","year":"2022","unstructured":"\u00c7\u0131nar E et al (2022) Neuroinflammation in Parkinson\u2019s disease and its treatment opportunities. Balkan Med J 39(5):318\u2013333","journal-title":"Balkan Med J"},{"issue":"2","key":"1961_CR11","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1002\/jcph.1008","volume":"58","author":"LD Coles","year":"2018","unstructured":"Coles LD et al (2018) Repeated-dose oral N-acetylcysteine in Parkinson\u2019s disease: pharmacokinetics and effect on brain glutathione and oxidative stress. J Clin Pharmacol 58(2):158\u2013167","journal-title":"J Clin Pharmacol"},{"issue":"16","key":"1961_CR12","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1001\/jama.2014.3654","volume":"311","author":"BS Connolly","year":"2014","unstructured":"Connolly BS, Lang AE (2014) Pharmacological treatment of Parkinson disease: a review. JAMA 311(16):1670\u20131683","journal-title":"JAMA"},{"issue":"8","key":"1961_CR14","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/S1474-4422(15)00006-X","volume":"14","author":"B Dehay","year":"2015","unstructured":"Dehay B et al (2015) Targeting alpha-synuclein for treatment of Parkinson\u2019s disease: mechanistic and therapeutic considerations. Lancet Neurol 14(8):855\u2013866","journal-title":"Lancet Neurol"},{"issue":"9","key":"1961_CR15","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMoa060281","volume":"355","author":"G Deuschl","year":"2006","unstructured":"Deuschl G et al (2006) A randomized trial of deep-brain stimulation for Parkinson\u2019s disease. N Engl J Med 355(9):896\u2013908","journal-title":"N Engl J Med"},{"issue":"2","key":"1961_CR16","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/j.1471-4159.1989.tb09133.x","volume":"52","author":"DT Dexter","year":"1989","unstructured":"Dexter DT et al (1989) Basal lipid peroxidation in substantia nigra is increased in Parkinson\u2019s disease. J Neurochem 52(2):381\u2013389","journal-title":"J Neurochem"},{"key":"1961_CR17","unstructured":"El-Habta R et al (2024) N-acetylcysteine protects human embryonic stem cell-derived midbrain dopaminergic neurons against dopamine-induced oxidative stress. Free Radic Biol Med [in press]"},{"issue":"4","key":"1961_CR18","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/s41582-019-0155-7","volume":"15","author":"A Elkouzi","year":"2019","unstructured":"Elkouzi A et al (2019) Emerging therapies in Parkinson disease \u2014 repurposed drugs and new approaches. Nat Rev Neurol 15(4):204\u2013223","journal-title":"Nat Rev Neurol"},{"issue":"9","key":"1961_CR19","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1093\/brain\/awx202","volume":"140","author":"JC Fitzgerald","year":"2017","unstructured":"Fitzgerald JC, Zimprich A, Carvajal Berrio DA et al (2017) Metformin reverses TRAP1 mutation-associated alterations in mitochondrial function in Parkinson\u2019s disease. Brain 140(9):2444\u20132459. https:\/\/doi.org\/10.1093\/brain\/awx202","journal-title":"Brain"},{"issue":"1","key":"1961_CR20","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13024-020-00367-7","volume":"15","author":"P Ge","year":"2020","unstructured":"Ge P et al (2020) PINK1 and Parkin mitochondrial quality control: a source of regional vulnerability in Parkinson\u2019s disease. Mol Neurodegener 15(1):20","journal-title":"Mol Neurodegener"},{"issue":"2","key":"1961_CR21","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.nbd.2005.08.002","volume":"21","author":"A Gerhard","year":"2006","unstructured":"Gerhard A et al (2006) In vivo imaging of microglial activation with [11\u00a0C](R)-PK11195 PET in idiopathic Parkinson\u2019s disease. Neurobiol Dis 21(2):404\u2013412","journal-title":"Neurobiol Dis"},{"issue":"11","key":"1961_CR22","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1016\/j.freeradbiomed.2010.08.028","volume":"49","author":"A Ghosh","year":"2010","unstructured":"Ghosh A, Chandran K, Kalivendi SV et al (2010) Neuroprotection by a mitochondria-targeted drug in a Parkinson\u2019s disease model. Free Radic Biol Med 49(11):1674\u20131684. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2010.08.028","journal-title":"Free Radic Biol Med"},{"issue":"7364","key":"1961_CR23","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/nature10368","volume":"477","author":"MR Hara","year":"2019","unstructured":"Hara MR et al (2019) A stress response pathway regulates DNA damage through \u03b22-adrenoreceptors and \u03b2-arrestin-1. Nature 477(7364):349\u2013353","journal-title":"Nature"},{"issue":"5","key":"1961_CR24","first-page":"2070","volume":"67","author":"TG Hastings","year":"1996","unstructured":"Hastings TG et al (1996) Oxidative modification and inactivation of tyrosine hydroxylase by dopamine-o-quinone. J Neurochem 67(5):2070\u20132079","journal-title":"J Neurochem"},{"issue":"4","key":"1961_CR25","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/S1474-4422(09)70062-6","volume":"8","author":"EC Hirsch","year":"2009","unstructured":"Hirsch EC, Hunot S (2009) Neuroinflammation in Parkinson\u2019s disease: a target for neuroprotection? Lancet Neurol 8(4):382\u2013397","journal-title":"Lancet Neurol"},{"key":"1961_CR26","unstructured":"Hoffman M (2023) Biogen and Denali terminate phase 3 LIGHTHOUSE study of BIIB122 in LRRK2-related Parkinson disease. NeurologyLive. https:\/\/www.neurologylive.com\/view\/biogen-denali-terminate-phase-3-lighthouse-study-biib122-lrrk2-parkinson-disease. Accessed 23 Sep 2025"},{"issue":"4","key":"1961_CR27","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/WNF.0b013e31829ae713","volume":"36","author":"MJ Holmay","year":"2013","unstructured":"Holmay MJ, Terpstra M, Coles LD et al (2013) N-acetylcysteine boosts brain and blood glutathione in Gaucher and Parkinson diseases. Clin Neuropharmacol 36(4):103\u2013106. https:\/\/doi.org\/10.1097\/WNF.0b013e31829ae713","journal-title":"Clin Neuropharmacol"},{"key":"1961_CR28","doi-asserted-by":"publisher","first-page":"109952","DOI":"10.1016\/j.neuropharm.2024.109952","volume":"253","author":"C H\u00f6lscher","year":"2024","unstructured":"H\u00f6lscher C (2024) Glucagon-like peptide-1 class drugs show clear protective effects in Parkinson\u2019s and Alzheimer\u2019s disease clinical trials: a revolution in the making? Neuropharmacology 253:109952. https:\/\/doi.org\/10.1016\/j.neuropharm.2024.109952","journal-title":"Neuropharmacology"},{"issue":"10","key":"1961_CR29","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1001\/jamaneurol.2018.1487","volume":"75","author":"J Jankovic","year":"2018","unstructured":"Jankovic J, Goodman I, Safirstein B, Marmon TK, Schenk DB, Koller M et al (2018) Safety and tolerability of multiple ascending doses of PRX002\/RG7935, an anti\u2013\u03b1-synuclein monoclonal antibody, in patients with Parkinson disease: a randomized clinical trial. JAMA Neurol 75(10):1206\u20131214","journal-title":"JAMA Neurol"},{"issue":"648","key":"1961_CR30","doi-asserted-by":"publisher","first-page":"eabj2658","DOI":"10.1126\/scitranslmed.abj2658","volume":"14","author":"D Jennings","year":"2022","unstructured":"Jennings D et al (2022) Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson\u2019s disease. Sci Transl Med 14(648):eabj2658","journal-title":"Sci Transl Med"},{"issue":"2","key":"1961_CR31","first-page":"384","volume":"22","author":"D Jennings","year":"2023","unstructured":"Jennings D et al (2023) BIIB122, a selective LRRK2 inhibitor, in asymptomatic carriers of LRRK2 mutations: a randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurol 22(2):384\u2013395","journal-title":"Lancet Neurol"},{"issue":"9996","key":"1961_CR32","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","volume":"386","author":"LV Kalia","year":"2015","unstructured":"Kalia LV, Lang AE (2015) Parkinson\u2019s disease. Lancet 386(9996):896\u2013912","journal-title":"Lancet"},{"issue":"5","key":"1961_CR33","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/s41593-022-01061-1","volume":"25","author":"T Kamath","year":"2022","unstructured":"Kamath T, Abdulraouf A, Burris SJ et al (2022) Single-cell genomic profiling of human dopamine neurons identifies a population that selectively degenerates in Parkinson\u2019s disease. Nat Neurosci 25(5):588\u2013595. https:\/\/doi.org\/10.1038\/s41593-022-01061-1","journal-title":"Nat Neurosci"},{"issue":"9","key":"1961_CR34","first-page":"1287","volume":"19","author":"YS Kim","year":"2005","unstructured":"Kim YS et al (2005) A pivotal role of matrix metalloproteinase-3 activity in dopaminergic neuronal degeneration via microglial activation. FASEB J 19(9):1287\u20131289","journal-title":"FASEB J"},{"issue":"16","key":"1961_CR35","doi-asserted-by":"crossref","first-page":"8697","DOI":"10.3390\/ijms22168697","volume":"22","author":"K Kim","year":"2021","unstructured":"Kim K et al (2021) Mitochondria-targeting compounds in Parkinson\u2019s disease. Int J Mol Sci 22(16):8697","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1961_CR36","doi-asserted-by":"publisher","first-page":"a008888","DOI":"10.1101\/cshperspect.a008888","volume":"2","author":"C Klein","year":"2012","unstructured":"Klein C, Westenberger A (2012) Genetics of Parkinson\u2019s disease. Cold Spring Harb Perspect Med 2(1):a008888. https:\/\/doi.org\/10.1101\/cshperspect.a008888","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"7","key":"1961_CR37","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S1470-2045(15)00027-3","volume":"16","author":"S Kordes","year":"2015","unstructured":"Kordes S, Pollak MN, Zwinderman AH et al (2015) Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol 16(7):839\u2013847. https:\/\/doi.org\/10.1016\/S1470-2045(15)00027-3","journal-title":"Lancet Oncol"},{"issue":"5","key":"1961_CR38","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1002\/mds.27360","volume":"33","author":"AE Lang","year":"2018","unstructured":"Lang AE, Espay AJ (2018) Disease modification in Parkinson\u2019s disease: current approaches, challenges, and future considerations. Mov Disord 33(5):660\u2013677","journal-title":"Mov Disord"},{"issue":"4","key":"1961_CR39","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1002\/1531-8249(199910)46:4<598::AID-ANA7>3.0.CO;2-F","volume":"46","author":"JW Langston","year":"1999","unstructured":"Langston JW et al (1999) Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol 46(4):598\u2013605","journal-title":"Ann Neurol"},{"issue":"3","key":"1961_CR40","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1007\/s12640-019-00015-z","volume":"36","author":"MC Leal","year":"2019","unstructured":"Leal MC, Surace EI, Bhatt DL, Lee DC, Bhatt DL, Bhatt DL (2019) The neuroprotective effect of doxycycline on neurodegenerative diseases. Neurotox Res 36(3):638\u2013645. https:\/\/doi.org\/10.1007\/s12640-019-00015-z","journal-title":"Neurotox Res"},{"issue":"7312","key":"1961_CR41","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/nature09299","volume":"467","author":"BH Lee","year":"2010","unstructured":"Lee BH, Lee MJ, Park S et al (2010) Enhancement of proteasome activity by a small-molecule inhibitor of USP14. Nature 467(7312):179\u2013184. https:\/\/doi.org\/10.1038\/nature09299","journal-title":"Nature"},{"issue":"9680","key":"1961_CR42","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1016\/S0140-6736(09)60492-X","volume":"373","author":"AJ Lees","year":"2009","unstructured":"Lees AJ, Hardy J, Revesz T (2009) Parkinson\u2019s disease. Lancet 373(9680):2055\u20132066. https:\/\/doi.org\/10.1016\/S0140-6736(09)60492-X","journal-title":"Lancet"},{"key":"1961_CR43","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1038\/s41467-018-04422-2","volume":"9","author":"MHR Ludtmann","year":"2018","unstructured":"Ludtmann MHR, Angelova PR, Horrocks MH, Choi ML, Rodrigues M, Baev AY, Berezhnov AV, Yao Z, Little D, Banushi B, Al-Menhali AS, Ranasinghe RT, Whiten DR, Yapom R, Dolt KS, Devine MJ, Gissen P, Kunath T, Jaganjac M, Gandhi S (2018) \u03b1-synuclein oligomers interact with ATP synthase and open the permeability transition pore in Parkinson\u2019s disease. Nat Commun 9:2293. https:\/\/doi.org\/10.1038\/s41467-018-04422-2","journal-title":"Nat Commun"},{"issue":"6109","key":"1961_CR44","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1126\/science.1227157","volume":"338","author":"KC Luk","year":"2012","unstructured":"Luk KC et al (2012) Pathological \u03b1-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338(6109):949\u2013953","journal-title":"Science"},{"issue":"4","key":"1961_CR45","first-page":"1489","volume":"147","author":"A Martirosyan","year":"2024","unstructured":"Martirosyan A et al (2024) Transcriptomic analysis reveals GABAergic neuronal vulnerability in the Parkinson\u2019s disease substantia nigra. Brain 147(4):1489\u20131503","journal-title":"Brain"},{"issue":"5","key":"1961_CR46","first-page":"879","volume":"14","author":"K McFarthing","year":"2024","unstructured":"McFarthing K et al (2024) Parkinson\u2019s disease drug therapies in the clinical trial pipeline: 2024 update. J Parkinsons Dis 14(5):879\u2013904","journal-title":"J Parkinsons Dis"},{"issue":"1","key":"1961_CR47","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1006\/exnr.2002.8050","volume":"179","author":"KSP McNaught","year":"2003","unstructured":"McNaught KSP, Belizaire R, Isacson O, Jenner P, Olanow CW (2003) Altered proteasomal function in sporadic Parkinson\u2019s disease. Exp Neurol 179(1):38\u201346. https:\/\/doi.org\/10.1006\/exnr.2002.8050","journal-title":"Exp Neurol"},{"issue":"5","key":"1961_CR48","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1093\/brain\/awu020","volume":"137","author":"A McNeill","year":"2014","unstructured":"McNeill A, Magalhaes J, Shen C, Chau KY, Hughes D, Mehta A et al (2014) Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells. Brain 137(5):1481\u20131495","journal-title":"Brain"},{"issue":"13","key":"1961_CR49","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1056\/NEJMoa2312323","volume":"390","author":"WG Meissner","year":"2024","unstructured":"Meissner WG et al (2024) Trial of lixisenatide in early Parkinson\u2019s disease. N Engl J Med 390(13):1176\u20131185","journal-title":"N Engl J Med"},{"issue":"4","key":"1961_CR50","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.neuron.2016.03.038","volume":"90","author":"PP Michel","year":"2016","unstructured":"Michel PP, Hirsch EC, Hunot S (2016) Understanding dopaminergic cell death pathways in Parkinson disease. Neuron 90(4):675\u2013691. https:\/\/doi.org\/10.1016\/j.neuron.2016.03.038","journal-title":"Neuron"},{"issue":"5","key":"1961_CR51","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1002\/ana.24790","volume":"80","author":"A Migdalska-Richards","year":"2016","unstructured":"Migdalska-Richards A et al (2016) Ambroxol effects in glucocerebrosidase and \u03b1-synuclein transgenic mice. Ann Neurol 80(5):766\u2013775","journal-title":"Ann Neurol"},{"issue":"6","key":"1961_CR52","doi-asserted-by":"publisher","first-page":"e0157602","DOI":"10.1371\/journal.pone.0157602","volume":"11","author":"DA Monti","year":"2016","unstructured":"Monti DA et al (2016) N-acetyl cysteine may support dopamine neurons in Parkinson\u2019s disease: preliminary clinical and cell line data. PLoS ONE 11(6):e0157602","journal-title":"PLoS ONE"},{"issue":"4","key":"1961_CR53","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1001\/jamaneurol.2019.4611","volume":"77","author":"S Mullin","year":"2020","unstructured":"Mullin S, Smith L, Lee K et al (2020) Ambroxol for the treatment of patients with Parkinson disease with and without glucocerebrosidase gene mutations: a nonrandomized, noncontrolled trial. JAMA Neurol 77(4):427\u2013434. https:\/\/doi.org\/10.1001\/jamaneurol.2019.4611","journal-title":"JAMA Neurol"},{"key":"1961_CR54","doi-asserted-by":"crossref","unstructured":"Nagatsu T, Mogi M, Ichinose H, Togari A (2000) Changes in cytokines and neurotrophins in Parkinson\u2019s disease. Adv Res Neurodegener (60):277\u2013290","DOI":"10.1007\/978-3-7091-6301-6_19"},{"key":"1961_CR55","first-page":"1","volume":"3","author":"Z Ortega","year":"2010","unstructured":"Ortega Z et al (2010) Ubiquitin-proteasome system involvement in Huntington\u2019s disease. Front Mol Neurosci 3:1\u201312","journal-title":"Front Mol Neurosci"},{"key":"1961_CR56","first-page":"521","volume":"9","author":"P Pantziarka","year":"2018","unstructured":"Pantziarka P et al (2018) Repurposing drugs in oncology (ReDO)\u2014itraconazole as an anti-cancer agent. eCancerMedicalScience 9:521","journal-title":"eCancerMedicalScience"},{"issue":"1","key":"1961_CR57","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41531-025-00954-z","volume":"11","author":"L Phan","year":"2025","unstructured":"Phan L, Miller D, Gopinath A et al (2025) Parkinson\u2019s paradox: alpha-synuclein\u2019s selective strike on SNc dopamine neurons over VTA. npj Parkinsons Dis 11(1):207. https:\/\/doi.org\/10.1038\/s41531-025-00954-z","journal-title":"npj Parkinsons Dis"},{"issue":"1","key":"1961_CR58","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","volume":"18","author":"S Pushpakom","year":"2018","unstructured":"Pushpakom S et al (2018) Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov 18(1):41\u201358","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"1961_CR59","first-page":"609","volume":"121","author":"M Regensburger","year":"2014","unstructured":"Regensburger M et al (2014) The role of dopaminergic innervation of the subthalamic nucleus and ventral mesencephalic dopamine neurons in Parkinson\u2019s disease. J Neural Transm 121(6):609\u2013614","journal-title":"J Neural Transm"},{"issue":"4","key":"1961_CR60","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1007\/s13311-014-0294-x","volume":"11","author":"F Richter","year":"2014","unstructured":"Richter F, Fleming SM, Watson M et al (2014) A GCase chaperone improves motor function in a mouse model of synucleinopathy. Neurotherapeutics 11(4):840\u2013856. https:\/\/doi.org\/10.1007\/s13311-014-0294-x","journal-title":"Neurotherapeutics"},{"issue":"7827","key":"1961_CR61","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41586-020-2577-1","volume":"586","author":"L Riva","year":"2020","unstructured":"Riva L et al (2020) Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. Nature 586(7827):113\u2013119","journal-title":"Nature"},{"issue":"8","key":"1961_CR62","first-page":"1540","volume":"25","author":"C Rotermund","year":"2018","unstructured":"Rotermund C et al (2018) The specific metabolic states associated with PD cell death are determined by the metabolic adaptation capacity and the choice of cell death pathway. Cell Death Differ 25(8):1540\u20131553","journal-title":"Cell Death Differ"},{"issue":"3","key":"1961_CR63","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1111\/j.1471-4159.1990.tb02325.x","volume":"54","author":"AH Schapira","year":"1990","unstructured":"Schapira AH et al (1990) Mitochondrial complex I deficiency in Parkinson\u2019s disease. J Neurochem 54(3):823\u2013827","journal-title":"J Neurochem"},{"issue":"3","key":"1961_CR64","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/ana.410360305","volume":"36","author":"J Sian","year":"1994","unstructured":"Sian J et al (1994) Alterations in glutathione levels in Parkinson\u2019s disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 36(3):348\u2013355","journal-title":"Ann Neurol"},{"issue":"8","key":"1961_CR65","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1001\/jamaneurol.2025.1687]","volume":"82","author":"CRA Silveira","year":"2025","unstructured":"Silveira CRA, Coleman KKL, Borron K et al (2025) Ambroxol as a treatment for Parkinson disease dementia: a randomized clinical trial. JAMA Neurol 82(8):797\u2013807. https:\/\/doi.org\/10.1001\/jamaneurol.2025.1687]","journal-title":"JAMA Neurol"},{"issue":"11","key":"1961_CR66","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1002\/mds.23148","volume":"25","author":"BJ Snow","year":"2010","unstructured":"Snow BJ, Rolfe FL, Lockhart MM, Frampton CM, O\u2019Sullivan JD, Fung V, Smith RAJ, Murphy MP, Taylor KM (2010) A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson\u2019s disease. Mov Disord 25(11):1670\u20131674. https:\/\/doi.org\/10.1002\/mds.23148","journal-title":"Mov Disord"},{"issue":"6645","key":"1961_CR67","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/42166","volume":"388","author":"MG Spillantini","year":"1997","unstructured":"Spillantini MG et al (1997) Alpha-synuclein in Lewy bodies. Nature 388(6645):839\u2013840","journal-title":"Nature"},{"issue":"2","key":"1961_CR68","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nrn.2016.178","volume":"18","author":"DJ Surmeier","year":"2017","unstructured":"Surmeier DJ et al (2017) Selective neuronal vulnerability in Parkinson disease. Nat Rev Neurosci 18(2):101\u2013113","journal-title":"Nat Rev Neurosci"},{"issue":"1","key":"1961_CR69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1021\/acschemneuro.3c00531","volume":"16","author":"R Tenchov","year":"2025","unstructured":"Tenchov R et al (2025) Parkinson\u2019s disease: review of pathophysiology, genetic landscape, clinical features, and current therapeutic approaches. ACS Chem Neurosci 16(1):1\u201320","journal-title":"ACS Chem Neurosci"},{"key":"1961_CR70","first-page":"175628642312003","volume":"16","author":"MI Tolea","year":"2023","unstructured":"Tolea MI et al (2023) Ambroxol in Alzheimer\u2019s disease and Parkinson\u2019s disease: a systematic review of clinical studies. Ther Adv Neurol Disord 16:17562864231200389","journal-title":"Ther Adv Neurol Disord"},{"issue":"10479","key":"1961_CR71","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/S0140-6736(24)02808-3","volume":"405","author":"N Vijiaratnam","year":"2025","unstructured":"Vijiaratnam N, Girges C, Auld G et al (2025) Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson\u2019s disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial. Lancet 405(10479):627\u2013636. https:\/\/doi.org\/10.1016\/S0140-6736(24)02808-3","journal-title":"Lancet"},{"issue":"2","key":"1961_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nm.4269","volume":"23","author":"YC Wong","year":"2017","unstructured":"Wong YC, Krainc D (2017) \u03b1-Synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies. Nat Med 23(2):1\u201313","journal-title":"Nat Med"},{"key":"1961_CR74","unstructured":"World Health Organization (2025) Parkinson disease. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/parkinson-disease. Accessed 29 Sep 2025"},{"issue":"9","key":"1961_CR73","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1001\/jama.2020.1166","volume":"323","author":"OJ Wouters","year":"2020","unstructured":"Wouters OJ et al (2020) Estimated research and development investment needed to bring a new medicine to market, 2009\u20132018. JAMA 323(9):844\u2013853","journal-title":"JAMA"},{"issue":"11","key":"1961_CR75","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1080\/15548627.2016.1214777","volume":"12","author":"M Xilouri","year":"2016","unstructured":"Xilouri M et al (2016) Impairment of chaperone-mediated autophagy induces dopaminergic neurodegeneration in rats. Autophagy 12(11):2136\u20132154","journal-title":"Autophagy"},{"issue":"9","key":"1961_CR76","doi-asserted-by":"publisher","first-page":"4643","DOI":"10.3390\/ijms25094643","volume":"25","author":"LX Yi","year":"2024","unstructured":"Yi LX, Tan EK, Zhou ZD (2024) Tyrosine hydroxylase inhibitors and dopamine receptor agonists combination therapy for Parkinson\u2019s disease. Int J Mol Sci 25(9):4643. https:\/\/doi.org\/10.3390\/ijms25094643","journal-title":"Int J Mol Sci"},{"issue":"2","key":"1961_CR77","first-page":"211","volume":"592","author":"F Yin","year":"2014","unstructured":"Yin F et al (2014) Mitochondrial function in ageing: coordination with signalling and epigenetic pathways. J Physiol 592(2):211\u2013234","journal-title":"J Physiol"}],"container-title":["Metabolic Brain Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11011-026-01961-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11011-026-01961-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11011-026-01961-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T03:38:20Z","timestamp":1788925100000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11011-026-01961-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":76,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1961"],"URL":"https:\/\/doi.org\/10.1007\/s11011-026-01961-2","relation":{},"ISSN":["1573-7365"],"issn-type":[{"value":"1573-7365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]},"assertion":[{"value":"13 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Permission from the Institutional Ethical Committee is not required for this review article.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"209"}}